In order to strengthen its presence in the health software market, the Equasens group based in Villers-lès-Nancy announces the acquisition of 90% of the capital of Calimed SAS, a pure player in the field of publishing management software. 100% cloud firm (LGC) operating under the Calimed Santé brand.
The entity based in Marseille and founded in 2007 allows general practitioners and specialists to manage their patient files (prescriptions, pre and post-operative questionnaires, etc.), their consultation schedule, their accounting, etc. The acquisition of Calimed, which has 4,000 active users on its solutions, will allow Equasens to increase its market share and expand its portfolio of online solutions to support the digital transition of doctors.
“An important step in the deployment of our strategy”
“The acquisition of Calimed is an important step in the deployment of our “Patient-Centered” strategy for healthcare professionals and establishments. This acquisition strengthens our portfolio of innovative Cloud solutions for surgeons and private doctors, in addition to our current flagship offers. Users of Calimed and easy-care will see their software quickly enriched with additional modules published by Equasens such as Loquii and Pandalab Pro, in order to facilitate their practice and recover medical time,” indicates Denis Supplisson, general director of Equasens group in a press release.
The Equasens group specifies that “digitalization is emerging as a major lever for optimizing costs, streamlining care pathways and strengthening coordination between professionals. New regulations require open, secure and interoperable solutions, creating a strong dynamic of innovation and investment. »
The Meurthe-et-Mosellan group also recalls the economic development prospects linked to this acquisition: “With a total of 200,000 practitioners including 115,000 in private practice, the growth potential is significant. »
The Equasens group, which employs 1,300 employees in Europe, does not wish to communicate the financial details of this acquisition.
